1
|
Dominic JL, Kannan A, Tara A, Hakim Mohammed AR, Win M, Khorochkov A, Sultan W, Ahmed A, Kantamaneni K, Syzmanski MW, Singh R, Marquez RA, Asarian A, Thirunavukarasu P, Keckeisen G. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for the prevention and control of peritoneal metastasis in patients with gastrointestinal malignancies: a systematic review of randomized controlled trials. EXCLI JOURNAL 2021; 20:1328-1345. [PMID: 34650387 PMCID: PMC8495114 DOI: 10.17179/excli2021-4108] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 08/04/2021] [Indexed: 02/05/2023]
Abstract
Peritoneal metastasis is associated with poor prognosis, with studies in the literature reporting the survival of peritoneal metastasis without treatment to be three to six months. Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown positive outcomes by improving the prognosis in patients with gastrointestinal malignancies. This systematic review of randomized controlled trials was done to determine the prophylactic role of hyperthermic intraperitoneal chemotherapy in preventing and controlling peritoneal metastasis gastrointestinal origin. Randomized controlled trials published between January 2019 to June 2021 were included. The databases used were MEDLINE (PubMed), EMBASE (Ovid), and the Cochrane library. Cochrane handbook for systematic review of intervention was used to assess the risk of bias in included trials. The results were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. A total of five trials met the inclusion criteria. Two studies were on patients with gastric cancer, and the other three studies were on patients with colorectal cancer. HIPEC was given to a total of 116 gastric cancer patients and 308 colorectal cancer patients. In all the included studies on patients with gastric cancer, the peritoneal recurrence-free survival was significantly higher in the group that received HIPEC. There was no significant improvement in peritoneal-free survival in patients with colorectal cancer who received HIPEC. HIPEC appears to be effective in preventing peritoneal metastasis in patients with locally advanced gastric cancer without minimal postoperative complications. However, in patients with advanced colorectal malignancy, HIPEC does not seem to play a crucial role in preventing and controlling peritoneal metastasis.
Collapse
Affiliation(s)
- Jerry Lorren Dominic
- General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States
| | - Amudhan Kannan
- Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
| | - Anjli Tara
- General Surgery, California Institute of Behavioral Neurosciences and Psychology, Fairfield, California, United States
| | - Abdul Rub Hakim Mohammed
- Emergency Medicine, The George Washington University - Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, India
| | - Myat Win
- General Surgery, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
| | - Arseni Khorochkov
- General Surgery, California Institute of Behavioral Neurosciences and Psychology, Fairfield, California, United States
| | - Waleed Sultan
- General Surgery, Halifax Health Medical Center, Daytona Beach, Florida, United States
| | - Asma Ahmed
- General Surgery, University of Missouri - Kansas City, Missouri, United States
| | - Ketan Kantamaneni
- General Surgery, Dr. Pinnamaneni Siddhartha Institute of Medical Sciences & Research Foundation, Gannavaram, Andhra Pradesh, India
| | - Michael W. Syzmanski
- General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States
| | - Rajbir Singh
- General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States
| | - Raul A. Marquez
- Orthopedic Surgery, Cornerstone Regional Hospital/South Texas Health System, Edinburg, Texas, United States
| | - Armand Asarian
- General Surgery, The Brooklyn Hospital Center, Brooklyn, New York, United States
| | - Pragatheeshwar Thirunavukarasu
- Director of Surgical Oncology, Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States and Adjunct Clinical Assistant Professor of Surgery, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, United States
- *To whom correspondence should be addressed: Pragatheeshwar Thirunavukarasu, Director of Surgical Oncology, Cape Fear Valley Medical Center, Fayetteville, North Carolina, United States; Adjunct Clinical Assistant Professor of Surgery, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, United States; Tel.: +1 910-987-5706, E-mail:
| | - George Keckeisen
- General Surgery, Stony Brook Medicine/Southampton Hospital, Southampton, New York, United States
| |
Collapse
|
2
|
Jouini R, Khanchel F, Sabbah M, Helal I, Gharsallah A, Ferchichi M, Hadded D, Zaafouri H, Ben Brahim E, Ben Maamer A, Debbiche AC. Prognostic significance of poorly cohesive gastric carcinoma in Tunisian patients. Heliyon 2020; 6:e03460. [PMID: 32195384 PMCID: PMC7078324 DOI: 10.1016/j.heliyon.2020.e03460] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 10/07/2019] [Accepted: 02/18/2020] [Indexed: 02/05/2023] Open
Abstract
Background While the incidence of gastric cancer has decreased worldwide in recent decades, the incidence of poorly cohesive carcinoma (PCC) is rising. The prognostic significance of gastric PCC remains a subject of debate. Objective To analyze the prognosis of gastric PCC in a Tunisian cohort. Methods A total of 122 gastric adenocarcinoma patients who underwent curative gastrectomy from 2001 to 2014 at Habib Thameur hospital in Tunis, Tunisia were included. The clinicopathological parameters and prognosis of PCC were analyzed in comparison with non PCC (NPCC). Results Sixty one patients (50%) presented PCC. Patients were younger in PCC group (p = 0,001). There was no difference in sex distribution between the two groups. PCC was more likely to be stage T4 (55.7% vs 34.4%; p = 0.033), N3 (67.8% vs 30%; p < 0.001) and have a higher metastatic lymph node ratio (p < 0.001). Hepatic metastases were more frequent in NPCC group (p = 0.031) whereas peritoneal carcinomatosis was more common in PCC group (p = 0.004). Perineural invasion was more frequent in PCC group (p = 0.001). Resection margins were more often positive in PCC group (31.1% vs 9.8%; p = 0.004). There was no difference in recurrence rate between the 2 groups (p = 0.348). The 5-year survival was similar in the NPCC and PCC (respectively 43% vs 23 %; p = 0.247). Survival rates were also comparable in early stage (100% vs 80% respectively for PCC and NPCC; p = 0.527) as well as for advanced stage (16% vs 35% respectively for PCC and NPCC; p = 0.538). PCC was not a prognostic factor for survival. Interestingly, advanced age, adjacent structures invasion, positive resection margins were specific prognostic factors for PCC. Conclusion In our study PCC was not a prognostic factor for survival. Advanced age, adjacent structures invasion and positive resection margins were specific prognostic features for this histological subtype.
Collapse
Affiliation(s)
- Raja Jouini
- Department of Pathology, Habib Thameur Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
- Corresponding author.
| | - Fatma Khanchel
- Department of Pathology, Habib Thameur Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
| | - Meriam Sabbah
- Department of Gastroenterology, Habib Thameur Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
| | - Imen Helal
- Department of Pathology, Habib Thameur Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
| | | | - Marwa Ferchichi
- Department of Pathology, Habib Thameur Hospital, Tunis, Tunisia
- Faculty of Sciences of Tunis, Tunis El Manar University, Tunisia
| | - Dhafer Hadded
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
- Department of Surgery, Habib Thameur Hospital, Tunisia
| | - Haithem Zaafouri
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
- Department of Surgery, Habib Thameur Hospital, Tunisia
| | - Ehsen Ben Brahim
- Department of Pathology, Habib Thameur Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
| | - Anis Ben Maamer
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
- Department of Surgery, Habib Thameur Hospital, Tunisia
| | - Aschraf Chadli Debbiche
- Department of Pathology, Habib Thameur Hospital, Tunis, Tunisia
- Faculty of Medicine of Tunis, Tunis El Manar University, Tunisia
| |
Collapse
|
3
|
Chen R, Chen QT, Dong YH. Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17. Oncol Lett 2019; 17:5447-5452. [PMID: 31186764 PMCID: PMC6507486 DOI: 10.3892/ol.2019.10270] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Accepted: 03/22/2019] [Indexed: 01/20/2023] Open
Abstract
Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on the levels of serum IL-17 were investigated. A retrospective analysis was performed on 129 patients who had metastatic gastric cancer after first-line chemotherapy and were treated in Xiangyang No. 1 People's Hospital from February 2012 to February 2015. Of these patients, 78 received oral apatinib and were assigned to experimental group; and 51 received oral tegafur-gimeracil-oteracil and were assigned to control group. Clinical efficacy was compared between the two groups, and the levels of serum IL-17 were measured for all the patients. The treatment response rate in the experimental group was 52.56% and in the control group 31.37%. Apparently, the treatment response rate in the experimental group was higher than that in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse drug reactions in the experimental group was significantly lower than that in the control group (P<0.05). The serum level of IL-17 after one course of medication was significantly lower than that before medication in both groups (P<0.05). In comparison between groups, the serum level of IL-17 after one course of medication was clearly lower in the experimental group than that in the control group (P<0.05). Apatinib regimen was demonstrated to have less toxic side-effects in the treatment of metastatic gastric cancer than tegafur-gimeracil-oteracil regimen, indicating that apatinib has favorable safety. In addition, apatinib can downregulate IL-17 expression, which is helpful in attenuating tumor proliferation and improving the clinical efficacy. Therefore, apatinib has potential use in a wide range of clinical applications.
Collapse
Affiliation(s)
- Ran Chen
- Department of Oncology, Xiangyang No. 1 People's Hospital, Huibei University of Medicine, Xiangyang, Hubei 441000, P.R. China
| | - Qi-Tian Chen
- Department of Oncology, Xiangyang No. 1 People's Hospital, Huibei University of Medicine, Xiangyang, Hubei 441000, P.R. China
| | - You-Hong Dong
- Department of Oncology, Xiangyang No. 1 People's Hospital, Huibei University of Medicine, Xiangyang, Hubei 441000, P.R. China
| |
Collapse
|
4
|
Kanak MA, Shindo Y, SaiKumar P, Naziruddin B. Role of Inflammasomes in the Development of Gastrointestinal Diseases. EXPERIENTIA SUPPLEMENTUM (2012) 2018; 108:235-268. [PMID: 30536174 DOI: 10.1007/978-3-319-89390-7_10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Many diseases of the gastrointestinal tract have been attributed to chronic inflammation, and a few have identified the role of inflammasomes in their pathogenesis. Inflammasomes are a group of protein complexes comprising of several intracellular proteins that link the sensing of microbial products and metabolic stress to the proteolytic activation of the proinflammatory cytokines. Recent studies have implicated activation of several families of NOD-like receptors (NLRs) which are major components of inflammasomes in the development and exacerbation of many diseases of human systems. In this chapter, we discuss the role of inflammasomes in some of the most prevalent diseases of the gastrointestinal tract and highlight potential targets for treatment.
Collapse
Affiliation(s)
- Mazhar A Kanak
- Division of Transplantation, Department of Surgery, Virginia Commonwealth University Medical Center, Richmond, VA, USA
| | - Yoshitaro Shindo
- Division of Transplantation, Department of Surgery, Virginia Commonwealth University Medical Center, Richmond, VA, USA
| | | | - Bashoo Naziruddin
- Sammons Cancer Center, Baylor Simmons Transplant Institute, Dallas, TX, USA.
| |
Collapse
|